



FACT SHEET

February 2006

Contact Information:


Liraz Kalif
Investor Relations
Teva Pharmaceutical Industries Ltd.
 Tel ++972-3-926-7281
 Fax ++972-3-926-7519
 E-mail: liraz.kalif@teva.co.il

Kevin Mannix
Director, Investor Relations
Teva North America
 Tel [215] 591-8912
 Fax [215] 591-8803
 E-mail: kevin.mannix@tevausa.com

website: www.tevapharm.com


Net Sales

(U.S. \$ in millions)




Net Income⁽¹⁾

(U.S. \$ in millions)




Earnings per ADR⁽¹⁾⁽²⁾

(in U.S. \$)



Shareholders' Equity

(U.S. \$ in millions)



(1) Before non-recurring items (after tax).

(2) Reflects the 2:1 stock splits (Dec. 2002, June 2004) and potential dilution of contingent convertible Debt.

A Company Overview

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva is one of the leading pharmaceutical companies in the world.

With over 100 years experience in the pharmaceutical industry, Teva enjoys a well-established international presence. Headquartered in Israel, close to 90% of Teva's sales, which totaled \$4.8 billion in 2004, are in North America and Europe. Teva has approximately 14,000 employees worldwide and production facilities in Israel, North America, Europe and Mexico.

In January 2006, the company closed its acquisition of IVAX Corporation, a U.S.-based generic provider of branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S., Central and Eastern Europe and Latin America among others.

With over \$7 billion in sales, operations in over 50 countries and approximately 25,000 employees worldwide, the newly combined company expands TEVA's leadership in global generics:

- Strengthens Teva's leading position in the U.S., the largest generic market in the world
- Expands Teva's leadership position in European generics – markets, which are poised for growth
- Transforms Teva's position in Latin America – through major expansion into new markets

The combined company offers the widest range of cost-effective pharmaceuticals, both generic and branded, to consumers, customers and healthcare providers. Teva is not simply an industry leader but the clear bellwether in its business.

Teva is the most actively traded share on the Tel-Aviv Exchange and among the most widely held Israeli shares on NASDAQ. Global institutional holdings are estimated to be two-thirds of Teva's shares, mostly by more than 600 U.S. institutions. Since November 2002, Teva's ADR is included in the NASDAQ-100 Index.


Market Data (as of February 24, 2006)

NASDAQ-100

Stock Symbol	TEVA
Recent Price	\$42.40
52 week range	\$27.48 - \$45.91
Market Capitalization	\$32 billion
# 14 in NASDAQ-100	

In-Market Global Sales of Copaxone®

(U.S. \$ in millions)





Recent Events

February 28, 2006 - Teva reported its fourth quarter 2005 financial results. Q4 sales amounted to \$1,401 million (up 6%). Net income and EPS reached \$305 million (up 9%) and \$0.45 (up 10%) respectively.

February 1, 2006 - Teva announced final results of merger consideration in connection with IVAX acquisition.

January 27, 2006 - Teva announces pricing of \$1.25 billion of convertible debentures.

January 27, 2006 - Teva announces pricing of \$1.5 billion of senior notes

January 27, 2006 - Teva announced favorable court decision regarding generic Allegra (Fexofenadine Hydrochloride Tablets); district court denies motion for preliminary injunction.

January 26, 2006 - Teva has completed its acquisition of IVAX Corporation.


January 25, 2006 - Teva announces offering of \$2.75 billion of senior notes and convertible debentures.

December 9, 2005 - Teva announces agreement with Cephalon regarding settlement of Provigil® patent litigation.

Sales by Region (U.S. \$ in millions)


2004: \$4,799 Million

- North America - 64%
- Europe - 26%
- Rest of the World - 10%



2005: \$5,250 Million

- North America - 60%
- Europe - 29%
- Rest of the World - 11%



Teva's Vision

Teva is a global Israeli-based pharmaceutical company. Its vision is to become one of the world's leading pharmaceutical companies, by being the undisputed leader in the global generics industry and by developing a global franchise in selected innovative products originating from Israeli science.

Teva differentiates itself by balancing its portfolio with generic and innovative activities, by the strategic depth of its vertical integration, by combining local customer responsiveness with a "global edge" and by successfully managing increasing profitable growth and complexity.

Our success lies in the leadership of our management, the skills and devotion of our people, the quality of our offerings and our focus on customers and patients.

U.S. Pipeline (as of February 24, 2006)

122 Filings
PLUS 38 TENTATIVE / APPROVABLE

88 of these 160 are paragraph IV filings

160 Filings Over \$94 Billion In Total Sales

49 First-To-File:
Over \$37 Billion In Total Sales

* Including products under the agreement with Andrx and Impax

FDA Approvals November 2005 – February 2006

Product		Approval/ Launch Date	Branded Product		Indication
			Brand	market size (\$ millions)	
Rabeprazole Sodium DR ⁽²⁾	Tab	02/06	Aciphex®	\$1,200	acid pump inhibitor
Adenosine ⁽²⁾	Inj	02/06	Adenoscan®	\$163	indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
Desmopressin Acetate	Tab	01/06	DDAVP®	\$202	indicated for management of central diabetes insipidus, temporary polyuria and polydipsia following head trauma or surgery in the pituitary region, and primary nocturnal enuresis.
Divalproex Sodium DR ⁽²⁾	Tab	01/06	Depakote®	\$813	indicated for treatment of manic episodes associated with bipolar disorder, prophylaxis of migraine headaches, and as therapy in several types of epileptic disorders
Simvastatin ⁽²⁾	Tab	12/05	Zocor®	\$4,385	Lipid lowering agent
Zonisamide	Caps	12/05	Zonegran®	\$174	Adjunct therapy in treatment of partial seizures in adults
Modafinil ⁽²⁾	Tab	12/05	Provigil®	\$543	To improve wakefulness in patients with excessive sleepiness associated with narcolepsy
Cefprozil ⁽¹⁾	Tab/ Oral Sus	12/05	Cefzil®	\$114/ \$116	Cephalosporin antibiotic
Oxycodone ⁽¹⁾	Tab	12/05	Oxycontin®	\$1200	Indicated for the treatment of moderate to severe pain when continuous analgesia is needed for an extended period of time.
Ribavirin ⁽¹⁾	Tab	12/05	Copegus®	\$203	Indicated for use in combination with peginterferon alfa-2a for treatment of adults with chronic hepatitis C virus who have compensated liver disease and have not been previously treated with interferon alpha.
Zaleplon ⁽²⁾	Caps	11/05	Sonata®	\$121	Indicated for short term treatment of insomnia.
Octreotide Acetate SDV ⁽¹⁾	Inj	11/05	Sandostatin®	\$80	Acromegaly; tx of diarrhea assoc w/ carcinoid tumors and vasoactive intestinal peptide tumors
Azithromycin ⁽¹⁾	Tab	11/05	Zithromax®	\$1600	Antibiotic

(1) Launched (2) Exclusivity (180 days) (3) Tentative approval